Hydroxychloroquine aplastic anemia

Discussion in 'Plaquenil' started by ru3000, 25-Feb-2020.

  1. e-pro XenForo Moderator

    Hydroxychloroquine aplastic anemia


    Detailed information on how Wiley uses cookies can be found in our Privacy Policy. 400-600 mg (310-465 mg base) PO daily for 4-12 weeks; maintenance: 200-400 mg (155-310 mg base) PO daily With prolonged therapy, obtain CBCs periodically 400 mg (310 mg base) PO once or twice daily; maintenance: 200-400 mg (155-310 mg base) PO daily With prolonged therapy, obtain CBCs periodically 100-200 mg (77.5-155 mg base) PO 2-3 times/wk Take with food or milk Nausea, vomiting Headache Dizziness Irritability Muscle weakness Aplastic anemia Leukopenia Thrombocytopenia Corneal changes or deposits (visual disturbances, blurred vision, photophobia; reversible on discontinuance) Retinal damage with long-term use Bleaching of hair Alopecia Pruritus Skin and musculoskeletal pigmentation changes Weight loss, anorexia Cardiomyopathy (rare) Hemolysis (individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency) Prolongs QT interval Ventricular arrhythmias and torsade de pointes Vertigo Tinnitus Nystagmus Nerve deafness Deafness Irreversible retinopathy with retinal pigmentation changes (bull’s eye appearance) Visual field defects (paracentral scotomas) Visual disturbances (visual acuity) Maculopathies (macular degeneration) Decreased dark adaptation Color vision abnormalities Corneal changes (edema and opacities) Abdominal pain Fatigue Liver function tests abnormal Hepatic failure acute Urticaria Angioedema Bronchospasm Decreased appetite Hypoglycemia Porphyria Weight decreased Sensorimotor disorder Skeletal muscle myopathy or neuromyopathy Headache Dizziness Seizure Ataxia Extrapyramidal disorders such as dystonia Dyskinesia Tremor Rash Pruritus Pigmentation disorders in skin and mucous membranes Hair color changes Alopecia Dermatitis bullous eruptions including erythema multiforme Stevens-Johnson syndrome Toxic epidermal necrolysis Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) Photosensitivity Dermatitis exfoliative Acute generalized exanthematous pustulosis (AGEP); AGEP has to be distinguished from psoriasis; hydroxychloroquine may precipitate attacks of psoriasis Pyrexia Hyperleukocytosis Hypersensitivity to 4-aminoquinoline derivatives Retinal or visual field changes due to 4-aminoquinoline compounds Long-term therapy in children Not effective against chloroquine-resistant strains of P. Individual plans may vary and formulary information changes.

    Can i have occasional glass wine plaquenil Chloroquine mechanism of action pdf

    Feb 19, 2020 SIDE EFFECTS. The following adverse reactions have been identified during post-approval use of PLAQUENIL or other 4-aminoqunoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The reported hematological side effects of hydroxychloroquine include aplastic anemia, agranulocytosis, thrombocytopenia, and hemolytic anemia in individuals with G-6-PD deficiency. However the frequency of secondary MDS after treatment with hydroxychloroquine is unknown. Sep 13, 2019 Applies to hydroxychloroquine oral tablet. Along with its needed effects, hydroxychloroquine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor immediately if any of the following side effects occur while taking hydroxychloroquine

    Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done. Falciparum Discontinue in 6 months if improvement is inadequate Use in patients with psoriasis may precipitate a severe attack of psoriasis; use with caution Postmarketing cases of life-threatening and fatal cardiomyopathy reported with use of hydroxychloroquine as well as of chloroquine Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease Ocular examination is recommended within first year of therapy; baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT) For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT; for individuals without significant risk factors, annual exams can usually be deferred until five years of treatment In individuals of Asian descent, retinal toxicity may first be noticed outside macula; in patients of Asian descent, it is recommended that visual field testing be performed in central 24 degrees instead of central 10 degrees Hydroxychloroquine should be discontinued if ocular toxicity is suspected and patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy Hepatic disease or alcoholism Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis and renal impairment; use with caution Dermatologic reactions to hydroxychloroquine may occur Patients are prone to dermatitis outbreaks Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment; clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during therapy; if cardiotoxicity is suspected, prompt discontinuation may prevent life-threatening complications Not for administration with other drugs that have potential to prolong QT interval; hydroxychloroquine prolongs QT interval; ventricular arrhythmias and torsades de pointes reported in patients taking hydroxychloroquine Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, reported; muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes; assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy Suicidal behavior rarely reported in patients treated with hydroxychloroquine Hematologic reactions (including aplastic anemia) and agranulocytosis may occur May exacerbate heart failure Shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications; warn patients about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment should have their blood glucose checked and treatment reviewed as necessary A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs Use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs Consider discontinuing therapy if any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, which is not attributable to the disease under treatment appears; perform periodic blood cell counts if patients are given prolonged therapy Pregnancy category: C Lactation: Drug is concentrated in breast milk (American Academy of Pediatrics committee states that it is compatible with nursing) A: Generally acceptable. Contact the applicable plan provider for the most current information.

    Hydroxychloroquine aplastic anemia

    Hydroxychloroquine Is Not Associated with Hemolytic Anemia., Secondary Myelodysplastic Syndrome after Hydroxychloroquine.

  2. Hydroxychloroquine sulfate allergy
  3. Summary Aplastic anemia is found among people who take Plaquenil, especially for people who are female, 30-39 old, have been taking the drug for 6 - 12 months, also take medication Prednisone, and have Paroxysmal nocturnal haemoglobinuria.

    • Will you have Aplastic anemia with Plaquenil - eHealthMe.
    • Hydroxychloroquine Side Effects Common, Severe, Long Term..
    • Examination of Hydroxychloroquine Use and Hemolytic Anemia..

    Oct 30, 2019 • Hematologic effects Bone marrow suppression eg, agranulocytosis, anemia, aplastic anemia, leukopenia, thrombocytopenia have been reported; periodically monitor CBC during prolonged therapy. Discontinue treatment if signs/symptoms of severe blood disorder not attributable to the underlying disease occur. Plaquenil® hydroxychloroquine sulfate is a white or practically white, crystalline powder, freely soluble in water; practically insoluble in alcohol, chloroform, and in ether. The chemical name for hydroxychloroquine sulfate is 2-4-7-Chloro-4-quinolylaminopentylethylamino ethanol sulfate 11. Aplastic anemia is a rare, non cancerous disorder where the blood marrow is unable to adequately produce blood cells required for survival. It is estimated that the incidence of aplastic anemia is 0.7-4.1 cases per million people worldwide with the prevalence between men and women being approximately equal.

     
  4. ruppc New Member

    Authors: Dr Anes Yang, Clinical Researcher, Department of Dermatology, St George Hospital, University of New South Wales, Sydney, NSW, Australia; Dr Monisha Gupta, Senior Staff Specialist, Department of Dermatology, Liverpool Hospital, Sydney, NSW, Australia. It is a hydroxylated version of chloroquine, with a similar mechanism of action. Hydroxychloroquine - Side Effects, Dosage, Interactions. Plaquenil and itching - Hydroxychloroquine Side Effects, Dosage, Uses, and More
     
  5. In some cases, they may not be available in every strength or form as the brand-name drug. Pompe Disease Symtoms, Causes, Treatments Glycogen Regulation and Storage Diseases - Quizlet Glycogen storage disease type II - Wikipedia
     
  6. kasperlet XenForo Moderator

    HYDROXYCHLOROQUINE - ORAL Plaquenil side effects. Consumer information about the medication HYDROXYCHLOROQUINE - ORAL Plaquenil, includes side effects, drug interactions, recommended dosages, and storage information. Read more about the prescription drug HYDROXYCHLOROQUINE - ORAL.

    Does Plaquenil affect your temperament? - LUPUS UK